NCT07101770 A Prediction Model in Pregnant Women With Aplastic Anemia
| NCT ID | NCT07101770 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Aplastic Anemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-11-27 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-11-27 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aplastic anemia (AA) is a rare haematologic disorder characterized by bone marrow failure and pancytopenia. Its occurrence during pregnancy is exceedingly rare but poses significant risks, including maternal hemorrhage, infections, and perinatal complications such as preterm birth and fetal growth restriction. Consequently, pregnancy with AA is highly perilous for both mothers and infants. Early management is critical to ensure the health of both the mother and the baby. However, there are currently no predictive tools available to assess adverse outcomes in pregnant women with AA. Our center plans to conduct a multicenter, combined retrospective and prospective cohort study.
Eligibility Criteria
Inclusion Criteria: 1. pregnant women who had aplastic anemia before pregnancy 2. pregnant women with newly diagnosed aplastic anemia during pregnancy Exclusion Criteria: 1. age less than 20 years 2. without coagulation series results 3. termination of pregnancy before 20 weeks of gestation 4. multiple pregnancy
Contact & Investigator
Xiaohui Zhang, MD
PRINCIPAL INVESTIGATOR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT07101770 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 50 Years, studying Aplastic Anemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07101770 currently recruiting?
Yes, NCT07101770 is actively recruiting participants. Contact the research team at zhangxh@bjmu.edu.cn for enrollment information.
Where is the NCT07101770 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07101770 clinical trial?
NCT07101770 is sponsored by Peking University People's Hospital. The principal investigator is Xiaohui Zhang, MD at Peking University People's Hospital. The trial plans to enroll 300 participants.